Christopher Durant Turner is Chief Medical Officer at Nuvalent, Inc. (NUVL). They have made 1 open-market trade across 1 company since 2023, most recently 2026-07-15.
CIK 0001862146
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NUVL | 14,350 | $1.8M |
Shares reported on the most recent Form 4, priced at the 2026-07-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NUVL | SELL | 2026-01-05 | 2026-01-07 | $97.25 | $721K | -0.1% | -2.3% | -3.6% |
| NUVL | SELL · 10b5-1 | 2025-01-06 | 2025-01-08 | $79.68 | $640K | +5.9% | +11.6% | -22.7% |
| NUVL | SELL · 10b5-1 | 2023-10-04 | 2023-10-06 | $53.85 | $775K | -14.4% | -9.4% | +17.2% |
| NUVL | SELL · 10b5-1 | 2023-07-26 | 2023-07-28 | $47.95 | $482K | -10.5% | -12.0% | +10.9% |
| NUVL | SELL · 10b5-1 | 2023-07-20 | 2023-07-24 | $46.81 | $14K | -0.7% | -7.4% | +9.9% |
| NUVL | SELL · 10b5-1 | 2023-06-05 | 2023-06-07 | $44.86 | $918K | +1.5% | -9.3% | +10.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.